Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cytrx Corp (CYTR)

Cytrx Corp (CYTR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced that its Board...

CYTR : 0.1089 (+14.63%)
CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to highlight the strategic...

CYTR : 0.1089 (+14.63%)
CytRx Partners with Oncology Development Expert to Advance LADR Platform

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it has partnered...

CYTR : 0.1089 (+14.63%)
CytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today issued the below letter to...

CYTR : 0.1089 (+14.63%)
CytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type C

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented...

ORPH : 0.8700 (-2.25%)
CYTR : 0.1089 (+14.63%)
CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted...

ORPH : 0.8700 (-2.25%)
CYTR : 0.1089 (+14.63%)
CytRx to Hold Town Hall for Stockholders on Thursday, January 20th

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories,...

CYTR : 0.1089 (+14.63%)
CytRx to Participate in the H.C. Wainwright BioConnect Virtual Conference

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories,...

CYTR : 0.1089 (+14.63%)
CytRx Announces the Appointment of Dr. Stephen Snowdy as Chief Executive Officer

CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development in oncology and neurodegenerative diseases, today announced...

VTI : 190.41 (-0.46%)
CYTR : 0.1089 (+14.63%)
CytRx Highlights ImmunityBio's Use of Aldoxorubicin in Ongoing Clinical Studies for Various Forms of Cancer

CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development in oncology and neurodegenerative diseases, today highlighted...

IBRX : 4.46 (+1.13%)
CYTR : 0.1089 (+14.63%)

Barchart Exclusives

Soft Commodities and Lumber in Q2
The soft commodities trade on the Intercontinental Exchange includes free-market sugar, Arabica coffee beans, cocoa beans, cotton, and frozen concentrated orange juice. Three of the five soft commodities fell in Q2 and over the first half of 2022. Lumber trades on the CME, and the price of wood suffered a significant decline in Q2 and since the end of 2021. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar